The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme; Myovant Sciences; Sanofi
Speakers' Bureau - Astellas Pharma; Exelixis; Genzyme; Genzyme (Inst); Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Exelixis; Janssen; Sanofi
 
Aniko Szabo
No Relationships to Disclose
 
Abhishek Tripathi
Honoraria - Urology times
Consulting or Advisory Role - Deka Biosciences; EMD Serono; Exelixis; Foundation Medicine; Genzyme; Pfizer; Seagen
Research Funding - Aravive (Inst); Bayer (Inst); Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Exact Sciences (Inst); Pfizer (Inst); WindMIL (Inst)
 
Asit K. Paul
Consulting or Advisory Role - Bayer; Genzyme; Tempus
 
Robert S. Alter
Consulting or Advisory Role - Bayer; Eisai; Janssen Biotech
Speakers' Bureau - Astellas Pharma; Aveo; Bayer; Bristol-Myers Squibb; Exelixis; Gilead Sciences; Pfizer
 
Kathryn A. Bylow
No Relationships to Disclose
 
Ariel Ann Nelson
No Relationships to Disclose
 
William A. Hall
Research Funding - Elekta (Inst)
Travel, Accommodations, Expenses - Elekta (Inst)
 
Peter Langenstroer
No Relationships to Disclose
 
Kenneth Jacobsohn
No Relationships to Disclose
 
Brian I. Rini
Leadership - MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - 3D Medicines; Aravive; Arrowhead Pharmaceuticals; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; GlaxoSmithKline; Merck; Pfizer; Shionogi; Surface Oncology; synthorx
Research Funding - Aravive (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); Surface Oncology (Inst); Taris (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Peter J. Van Veldhuizen
No Relationships to Disclose
 
Scott Johnson
No Relationships to Disclose
 
Nancy B. Davis
Consulting or Advisory Role - Janssen Biotech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst)
 
Chunkit Fung
Consulting or Advisory Role - Exelixis; Novartis; Novartis
Research Funding - Astellas Pharma (Inst)
 
Matthew I. Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Consulting or Advisory Role - Loxo/Lilly
Research Funding - Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); G1 Therapeutics (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape